ARNT and breast carcinoma: In HIF-1β negative cases, the status of HIF-1α and VEGF were as follows; 1/42 (2.4%) HIF-1α(+)/VEGF(+), 8/42 (19.1%) HIF-1α(-)/VEGF (+), 0/42 HIF-1α (+)/VEGF(-) and 6/42 (14.3%) HIF-1α(-)/VEGF(-) Table 4.Therefore, following correlation of HIF-1β status with HIF-1α in VEGF positive breast cancer revealed a statistically significant difference (p = 0.033; χ2 test).